檢索結果 - David M. Jackman

Refine Results
  1. 1
    Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations

    Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations 由 Elizabeth M Gaughan, Sarah K. Cryer, Beow Y. Yeap, David M. Jackman, Daniel B. Costa

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <i>EGFR</i> Mutations Treated with Gefitinib or Erlotinib

    Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <i>EGFR</i> Mutations Treated with Gefitinib or Erlotinib 由 Stéphanie Héon, Beow Y. Yeap, Gregory Joseph Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors 由 Sarah B. Goldberg, Geoffrey R. Oxnard, Subba R. Digumarthy, Alona Muzikansky, David M. Jackman, Inga T. Lennes, Lecia V. Sequist

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

    Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs 由 W. Marston Linehan, Stephanie Cardarella, Christine Lydon, Suzanne E. Dahlberg, David M. Jackman, Pasi A. Jänne, Bruce E. Johnson

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab

    Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab 由 Mizuki Nishinoa, Sarah K. Cryer, Yuka Okajim, Lynette M. Sholl, Hiroto Hatabu, Michael S. Rabin, David M. Jackman, Bruce E. Johnson

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI

    Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI 由 Mizuki Nishino, Suzanne E. Dahlberg, Stephanie Cardarella, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum

    Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum 由 Andrew G. Evans, Christopher A. French, Michael J. Cameron, Christopher D.�M. Fletcher, David M. Jackman, Christopher S. Lathan, Lynette M. Sholl

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival

    Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival 由 Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, Tetsuro Araki, Christine Lydon, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Bruce E. Johnson

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer 由 Peter Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne, Geoffrey R. Oxnard

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

    Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors 由 Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, David M. Jackman, Nikhil H. Ramaiya, Hiroto Hatabu, Michael S. Rabin, Pasi A. Jnne, Bruce E. Johnson

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC

    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC 由 Raymond H. Mak, Elizabeth Doran, Alona Muzikansky, Josephine Kang, Joel W. Neal, Noah C. Choi, Henning Willers, David M. Jackman, Lecia V. Sequist

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

    Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions 由 Geoffrey R. Oxnard, Peter Lo, Mizuki Nishino, Suzanne E. Dahlberg, Neal I. Lindeman, Mohit Butaney, David M. Jackman, Bruce E. Johnson, Pasi A. Jänne

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers

    Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers 由 Kimio Yonesaka, Kreshnik Zejnullahu, Neal I. Lindeman, Alison J. Homes, David M. Jackman, Feng Zhao, Andrew M. Rogers, Bruce E. Johnson, Pasi A. Jänne

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    <i>EGFR</i>Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

    <i>EGFR</i>Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry 由 Lynette M. Sholl, Yun Xiao, Victoria A. Joshi, Beow Y. Yeap, Leigh‐Anne Cioffredi, David M. Jackman, Charles Lee, Pasi A. Jänne, Neal I. Lindeman

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

    Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma 由 David M. Jackman, Hedy L. Kindler, Beow Y. Yeap, Panos Fidias, Ravi Salgia, Joan Lucca, Linda K. Morse, Patricia Ostler, Bruce E. Johnson, Pasi A. Jänne

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy

    New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Resp... 由 Mizuki Nishino, David M. Jackman, Hiroto Hatabu, Beow Y. Yeap, Leigh‐Anne Cioffredi, Jeffrey T. Yap, Pasi A. Jänne, Bruce E. Johnson, Annick D. Van den Abbeele

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

    Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer 由 David M. Jackman, William Pao, Gregory J. Riely, Jeffrey A. Engelman, Mark G. Kris, Pasi A. Jänne, Thomas J. Lynch, Bruce E. Johnson, Vincent A. Miller

    出版 2009
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

    The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations 由 Stéphanie Héon, Beow Y. Yeap, Neal I. Lindeman, Victoria A. Joshi, Mohit Butaney, Gregory Joseph Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

    The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer 由 Stephanie Cardarella, Taylor M. Ortiz, Victoria A. Joshi, Mohit Butaney, David M. Jackman, David J. Kwiatkowski, Beow Y. Yeap, Pasi A. Jänne, Neal I. Lindeman, Bruce E. Johnson

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib

    Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib 由 David M. Jackman, Alison J. Holmes, Neal I. Lindeman, Patrick Y. Wen, Santosh Kesari, Ana M. Borras, Christopher J. Bailey, Francisca de Jong, Pasi A. Jänne, Bruce E. Johnson

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: